Shots:

• Kymera to receive $70M upfront including equity investment- >$1B as development- regulatory & commercial milestones for up to 6 therapies opted by Vertex- royalties on sales of products and is responsible for clinical research activities. Vertex to get an option to license the developed molecules against designated targets
• The focus of the collaboration is to broaden the application of Kymera’s Pegasus drug discovery platform by developing therapies for serious diseases with limited/no treatment options
• Kymera’s Pegasus is a protein degradation platform consists of driven target identification- E3 ligases- ternary complex predictive modeling capabilities- and degradation tools accelerating the drug discovery process by targeting intractable of proteins

Ref: Vertex | Image: Vertex